---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-22-000021"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:11:27.376668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21

## Summary
- GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.
- Life Science segment sales $347.2M (-5.3% YoY); Clinical Diagnostics $351.8M (-1.9%).
- Full-year 2022 outlook: non-GAAP currency-neutral revenue growth ~1-2%; op margin ~19%.
- COVID-related revenue fell to ~$45M vs $94M in Q1 2021; core business grew 6.5% currency-neutral.
- Management notes macro risks: China lockdowns, Ukraine war, supply chain.

## SEC filing metadata
- accession: 0000012208-22-000021
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/0000012208-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/bio-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-22-000021
- JSON: https://secwatch.observer/filing/0000012208-22-000021.json
- Plain text: https://secwatch.observer/filing/0000012208-22-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.